By Fineline Cube 
Micot, a polypeptide new molecular entity (NME) drug developer with operations in mainland China, Hong Kong, and the US, reportedly secured over RMB 100 million (USD 14 million) in a Series D financing round led by Zheshang Venture Capital. The funds will be allocated to the research and development (R&D) of its polypeptide NME products and its Bio Res Deliv system, a biomacromolecules respiratory drug delivery platform.
Company Background
Founded in 2007, Micot is dedicated to the R&D of innovative drugs, including peptide protein biopharmaceuticals, vaccines, and biomolecular drug delivery systems. The company’s Bio Res Deliv system is designed to treat a range of conditions, including cardiovascular, metabolic, and liver diseases, highlighting its broad market potential.-Fineline Info & Tech